naa a22 4500 510748147 CHVBK 20180411083054.0 cr unu---uuuuu 180411e20130801xx s 000 0 ita 10.1007/s11547-012-0900-0 doi (NATIONALLICENCE)springer-10.1007/s11547-012-0900-0 Risultati clinici e fattori prognostici dopo radioterapia curativa nei pazienti con cancro anale: l'esperienza di una singola istituzione [Elektronische Daten] [M. Osti, L. Agolli, C. Scaringi, S. Bracci, G. Minniti, R. Maurizi Enrici] Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience Purpose: Our aim was to retrospectively analyse a series of patients with anal cancer treated with curative intent at a single institute in terms of survival and local disease control. Materials and methods: Forty-two patients with anal cancer were treated with primary radiotherapy with or without concurrent chemotherapy. The influence of the prognostic factors on overall (OS), disease-free (DFS), disease-specific (DSS), colostomy-free (CFS) and metastasis-free (MFS) survival was evaluated. Results: Nine patients had stage I, 15 stage II, four stage IIIA and 14 stage IIIB disease. Tumour progression/ persistence occurred in five patients (12%). The 5-year OS, DSS, DFS, CFS and MFS were 72.7%, 84.2%, 85.7%, 81.1% and 87.1%, respectively. On univariate analysis, T stage emerged as highly significant for OS, DSS, CFS and DFS, whereas N status was a significant prognostic factor for DSS. On multivariate analysis, T stage was a significant prognostic factor for OS and CFS. Conclusions: Our data support the view that combined chemoradiation treatment of anal cancer is feasible and may provide survival benefits with an acceptable rate of adverse effects. We should consider T and N stages as important prognostic factors for survival. Springer-Verlag Italia, 2012 Anal cancer nationallicence Radiotherapy nationallicence Chemotherapy nationallicence Prognostic factors nationallicence Cancro anale nationallicence Radioterapia nationallicence Chemioterapia nationallicence Fattori prognostici nationallicence Osti M. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut Agolli L. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut Scaringi C. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut Bracci S. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut Minniti G. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut Maurizi Enrici R. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut La radiologia medica Springer Milan 118/5(2013-08-01), 882-894 0033-8362 118:5<882 2013 118 11547 https://doi.org/10.1007/s11547-012-0900-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11547-012-0900-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Osti M. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 700 1- Agolli L. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 700 1- Scaringi C. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 700 1- Bracci S. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 700 1- Minniti G. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 700 1- Maurizi Enrici R. Department of Radiation Oncology, Sant'Andrea Hospital, "La Sapienza” University, Rome, Italy aut NATIONALLICENCE 773 0- La radiologia medica Springer Milan 118/5(2013-08-01), 882-894 0033-8362 118:5<882 2013 118 11547 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer